View Older Stories

Feb 26, 2026 06:02AM BeiGene, Ltd. (ONC) Tops Q4 EPS by 42c, provides guidance

Jan 13, 2026 06:01AM BeOne Medicines (ONC) BeOne Medicines presents oncology pipeline at JPMorgan conference

Jan 8, 2026 08:49AM 4Q25/2026 Biotech Earnings Preview: RBC

Jan 7, 2026 04:55AM BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens

Jan 6, 2026 03:56PM BofA on BeOne Medicines (ONC): 'we prefer BeOne, given the BTK leadership of Brukinsa and catalyst of BTK CDAC data readout'

Jan 6, 2026 01:31PM BeOne Medicines reports positive results from cancer drug trial

Dec 18, 2025 06:11AM BeOne Medicines (ONC)

Dec 17, 2025 07:37AM RBC Capital Reiterates Outperform Rating on BeOne Medicines (ONC)

Dec 11, 2025 04:09AM BeOne (ONC) Stock a Unique Buying Opportunity - Citizens

Nov 24, 2025 07:35AM Truist Securities Starts BeOne Medicines (ONC) at Buy

Nov 18, 2025 09:03AM BeOne Medicines (ONC) PT Raised to $408 at RBC Capital

Nov 17, 2025 02:59PM BeOne Medicines (ONC) PT Raised to $420 at Jefferies

Nov 7, 2025 02:18PM BeOne Medicines (ONC) PT Raised to $405 at Citi

Nov 6, 2025 06:04AM BeiGene, Ltd. (ONC) Tops Q3 EPS by 185c; updates guidance

Oct 20, 2025 06:01AM BeOne Medicines presents lung cancer data at ESMO 2025

Oct 13, 2025 06:00AM BeOne Medicines gets FDA breakthrough therapy status for cancer drug

Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview

Oct 9, 2025 08:21AM BeOne Medicines (ONC) PT Raised to $362 at Bernstein

Sep 18, 2025 02:51AM Barclays Starts BeOne Medicines (ONC) at Overweight

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Sep 9, 2025 04:12AM Citizens JMP Reiterates Market Outperform Rating on BeOne Medicines (ONC)

Aug 29, 2025 06:00AM BeOne Medicines reports positive results for lymphoma drug sonrotoclax

Aug 25, 2025 06:01AM BeOne Medicines sells IMDELLTRA royalty rights for up to $950 million

Aug 21, 2025 06:00AM BeOne Medicines gets EU approval for BRUKINSA tablet formulation

Aug 11, 2025 04:56PM Oncolytics Biotech shareholders elect eight directors at annual meeting

Aug 6, 2025 02:05PM BeOne Medicines (ONC) PT Raised to $365 at Guggenheim

Aug 6, 2025 06:03AM BeiGene, Ltd. (ONC) Misses Q2 EPS by 4c, provides guidance

Jul 31, 2025 06:01AM BeOne Medicines gets EU PRIME designation for blood cancer drug

Jul 29, 2025 08:30AM Oncolytics plans FDA talks for pancreatic cancer drug trial

Jul 28, 2025 06:02AM BeOne Medicines receives positive EU opinion for TEVIMBRA lung cancer use

Jul 16, 2025 12:00PM BeOne Medicines (ONC) PT Raised at RBC Capital; 'We See Continued HemeOnc Leadership'

Jul 10, 2025 06:00AM BeOne Medicines (ONC): European Commission approves TEVIMBRA for nasopharyngeal cancer treatment

Jul 1, 2025 04:09AM Citizens JMP Reiterates Market Outperform Rating on BeOne Medicines (ONC)

Jun 27, 2025 10:34AM RBC Capital Highlights BeOne Medicines' (ONC) Rich Pipeline

Jun 27, 2025 08:51AM Leerink Partners Reiterates Outperform Rating on BeOne Medicines (ONC)

Jun 26, 2025 06:02AM BeOne Medicines (ONC) Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

Jun 25, 2025 06:01AM BeOne Medicines (ONC) Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA

Jun 11, 2025 04:05PM FDA approves BeOne's (ONC) BRUKINSA tablet

May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025

May 7, 2025 06:01AM BeiGene, Ltd. (ONC) Tops Q1 EPS by $1.65, provides guidance

Apr 29, 2025 03:33PM BeiGene (ONC) Says U.S. Patent and Trademark Office Invalidated Pharmacyclics Patent

Apr 7, 2025 06:20AM RBC Capital Starts BeiGene Ltd. (ONC) at Outperform

Apr 4, 2025 04:32AM Citizens JMP Reiterates Market Outperform Rating on BeiGene Ltd. (ONC)

Apr 3, 2025 06:09AM BeiGene (ONC) Provides Update on the Ociperlimab Clinical Development Program

Mar 31, 2025 06:29AM BeiGene (ONC) Receives Positive CHMP Opinion for TEVIMBRA

Mar 13, 2025 10:42AM BeiGene Ltd. (ONC) PT Raised to $259 at Bernstein After 'Asset and Market Model Updates'

Mar 4, 2025 06:19AM Bank Of Commerce (ONC) Announces TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

Mar 3, 2025 04:19PM JPMorgan Reiterates Overweight Rating on BeiGene Ltd. (ONC), PT $311

Mar 3, 2025 04:25AM BofA Securities Upgrades BeiGene Ltd. (ONC) to Buy

Feb 28, 2025 07:58AM BeiGene Ltd. (ONC) PT Raised to $348 at Guggenheim

View Older Stories